Verify patient identity and consent. Confirm NPO status for 4 hours. Review current antiplatelet therapy (aspirin and clopidogrel/ticagrelor). Assess renal function and allergies. Ensure vascular access site is prepared and draped sterilely.
Monitor vital signs and access site for bleeding for 1-2 hours. Apply pressure dressing to the access site. Instruct patient to limit limb movement for 2 hours. Provide post-procedure antiplatelet regimen instructions and follow-up cardiology appointment. Discharge same day.
Comprehensive Clinical Guide: Percutaneous Coronary Intervention (PCI) with Bare Metal Stent (BMS)
Percutaneous Coronary Intervention (PCI), historically known as coronary angioplasty, remains a cornerstone of modern interventional cardiology. While the landscape of coronary revascularization has evolved toward Drug-Eluting Stents (DES), the Bare Metal Stent (BMS) retains a specific, critical role in the management of coronary artery disease (CAD). This guide provides an exhaustive clinical overview of the BMS, its mechanism, procedural application, and post-procedural management.
1. Introduction and Overview
A Bare Metal Stent (BMS) is a scaffold made of a metal alloy (typically stainless steel, cobalt-chromium, or platinum-chromium) designed to be deployed within a coronary artery following balloon angioplasty. Unlike its successor, the Drug-Eluting Stent (DES), the BMS does not possess a polymer coating or pharmacological agent to inhibit intimal hyperplasia.
The primary objective of a BMS is to provide mechanical radial support to the vessel wall, preventing elastic recoil and negative remodeling of the artery post-dilation. While the lack of anti-proliferative drugs makes them more susceptible to in-stent restenosis (ISR) compared to DES, they remain the gold standard in patients who cannot tolerate long-term Dual Antiplatelet Therapy (DAPT) due to high bleeding risks.
2. Technical Specifications and Mechanisms
The BMS functions through pure mechanical stabilization. The structural integrity of the stent is defined by several engineering factors that dictate its clinical performance.
Key Technical Attributes:
- Strut Thickness: Thicker struts provide greater radial strength but may induce more significant vascular injury and inflammatory response.
- Radiopacity: The ability of the stent to be visualized under fluoroscopy, crucial for precise placement.
- Flexibility and Deliverability: The ability of the stent to navigate tortuous coronary anatomy without losing its structural geometry.
- Biocompatibility: The chemical inertness of the metal alloy to prevent acute thrombosis.
The Mechanism of Action:
- Balloon Pre-dilation: A balloon catheter is inflated at the lesion site to fracture plaque and open the lumen.
- Stent Deployment: The BMS, mounted on a delivery balloon, is positioned across the lesion and expanded to the diameter of the reference vessel.
- Vessel Scaffolding: The stent provides immediate mechanical support, "tacking up" any coronary dissections and preventing the vessel from collapsing back into the lumen (elastic recoil).
- Endothelialization: Over several weeks, the stent struts are covered by a layer of neointima (endothelial cells), effectively burying the metal within the vessel wall.
3. Extensive Clinical Indications and Usage
The decision to utilize a BMS over a DES is based on a risk-benefit analysis regarding bleeding versus restenosis.
Primary Clinical Indications:
- High Bleeding Risk (HBR) Patients: Patients who require surgery soon after the procedure or those with a high risk of major bleeding complications, necessitating a shorter course of DAPT.
- Active Bleeding Disorders: Patients with coagulopathies where prolonged antiplatelet therapy is contraindicated.
- Non-Compliance Concerns: Patients where adherence to a long-term DAPT regimen (required for DES) is unlikely.
- Large Vessel Diameter: In very large coronary vessels where the risk of restenosis is lower.
Comparison Table: BMS vs. DES
| Feature | Bare Metal Stent (BMS) | Drug-Eluting Stent (DES) |
|---|---|---|
| Primary Mechanism | Mechanical Support | Mechanical + Pharmacological |
| Restenosis Rate | Higher (15-30%) | Lower (<10%) |
| DAPT Duration | 1 month minimum | 6–12 months minimum |
| Thrombosis Risk | Low (if DAPT is maintained) | Low (but late-stage risk exists) |
| Best For | HBR Patients / Short-term DAPT | Complex lesions / Chronic CAD |
4. Procedure: Pre-op, Intervention, and Recovery
Pre-Operative Preparation
- Antiplatelet Loading: Administration of Aspirin (325mg) and a P2Y12 inhibitor (e.g., Clopidogrel) prior to the procedure.
- Anticoagulation: Intravenous heparin or bivalirudin is administered to maintain an activated clotting time (ACT) of >250 seconds.
- Access Site Preparation: Radial artery access is preferred over femoral to minimize access-site bleeding complications.
Procedural Steps
- Coronary Angiography: Diagnostic imaging to confirm the site, length, and severity of the stenosis.
- Wire Crossing: A 0.014-inch guidewire is navigated across the target lesion.
- Lesion Preparation: Serial balloon inflations are performed to optimize the vessel for stent expansion.
- Deployment: The BMS is advanced over the wire, positioned under fluoroscopy, and deployed at high pressure.
- Post-dilation: A non-compliant balloon may be used to ensure full stent apposition against the vessel wall.
Post-Operative Recovery
- Hemostasis: Immediate removal of the sheath and application of a radial compression device (e.g., TR Band).
- Monitoring: 4–6 hours of bed rest and telemetry monitoring for arrhythmias or ischemic changes.
- Medication: Continuation of DAPT (Aspirin + P2Y12 inhibitor) for at least 30 days.
5. Risks, Side Effects, and Contraindications
While PCI is a routine procedure, it carries inherent risks.
Potential Complications
- Acute Vessel Closure: Usually due to dissection or acute stent thrombosis.
- In-Stent Restenosis (ISR): The formation of excessive scar tissue within the stent, requiring repeat revascularization.
- Vascular Access Complications: Hematoma, pseudoaneurysm, or radial artery occlusion.
- Contrast-Induced Nephropathy: Particularly in patients with pre-existing chronic kidney disease.
- Coronary Artery Perforation: A rare but catastrophic complication requiring immediate pericardiocentesis.
Contraindications
- Inability to tolerate DAPT: Even for one month.
- Diffuse, small-vessel disease: Where stenting is technically unfeasible.
- Severe allergy to metal alloys (e.g., Nickel, though rare).
6. Frequently Asked Questions (FAQ)
1. Why would a doctor choose a BMS instead of a modern DES?
The primary reason is the duration of blood-thinning medication. DES require long-term DAPT to prevent late stent thrombosis due to delayed healing caused by the drug coating. If a patient needs surgery soon or has a high bleeding risk, BMS is the safer choice.
2. How long does a BMS stay in the body?
A BMS is a permanent implant. It becomes incorporated into the wall of the artery as the vessel heals over it.
3. What is "In-Stent Restenosis"?
This is the narrowing of the stent lumen due to the overgrowth of smooth muscle cells (neointimal hyperplasia). It usually occurs within 6–12 months of the procedure.
4. Can I undergo an MRI with a BMS?
Yes, most modern BMS are considered "MR-Conditional." However, you must inform the radiologist of the date of the procedure and the specific type of stent used.
5. What happens if I stop taking my antiplatelet medication?
Stopping DAPT prematurely can lead to acute stent thrombosis—a life-threatening event where the stent suddenly clots, potentially causing a major heart attack.
6. Is BMS surgery "open heart"?
No, PCI is a minimally invasive endovascular procedure performed through a small puncture in the wrist or groin.
7. Does the stent cause chest pain?
The stent itself does not cause pain. However, if the artery renarrows (restenosis), the patient may experience recurrent angina.
8. How is the BMS sized?
Interventional cardiologists use Quantitative Coronary Angiography (QCA) or Intravascular Ultrasound (IVUS) to measure the diameter and length of the vessel accurately.
9. Will I need another procedure later?
While many patients do well for years, some may require repeat intervention if the stent develops restenosis or if new blockages develop elsewhere in the coronary tree.
10. Can I return to normal exercise after the procedure?
Most patients return to light activity within a few days. Strenuous exercise is typically restricted for 1–2 weeks to allow the access site to heal fully.
7. Conclusion
The Bare Metal Stent remains an indispensable tool in the interventional cardiologist’s armamentarium. By providing a reliable, purely mechanical solution for vessel patency, it bridges the gap for patients who are unsuitable candidates for the prolonged DAPT regimens required by Drug-Eluting Stents. As clinical practice moves toward personalized medicine, the BMS serves as a critical option for the High Bleeding Risk (HBR) population, ensuring that life-saving coronary revascularization remains accessible to all patients regardless of their pharmacological tolerance.
Medical Disclaimer: This guide is intended for educational and informational purposes for healthcare professionals and students. It does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition or procedural protocol.